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driving GFP expression. Puriﬁed cells were expanded and then cultured
as pellets for 3 wks in chondrogenic media containing dexamethasone
and TGF-b3, producing a robust cartilaginous matrix. As a model of OA,
pellets were cultured in standardmediawith IL-1a (0,10, or 100 pg/ml, or
1 ng/ml). After 3 days of culture, the elastic modulus of the pellets was
measured using atomic force microscopy, and the DNA, glycosamino-
glycan (GAG), and collagen contents of the pellets were analyzed bio-
chemically and histologically. Additionally, the media were collected and
analyzed for matrix metalloproteinase (MMP) activity and GAG, nitric
oxide (NO), and prostaglandin E2 (PGE2).
Results: Treatment of iPSC neocartilage with IL-1a produced a clear
degenerative response. MMP release was signiﬁcantly increased in all
treatment groups from a 27-fold increase at 10 pg to a 340-fold increase
at 1 ng/ml (Fig. 1A). The increase in MMPs was associated with a signiﬁ-
cant loss of GAGs from the pellet into themedia. IL-1a at a dose of 1 ng/ml
increased the percentage of total GAG in the media from 19% to 61% (Fig.
1B). Similar trends were apparent for the production of NO and PGE2,
with >6-fold increases at 1 ng/ml IL-1a. Histological analysis conﬁrmed
matrix degradation, with a dramatic decrease in sulfated GAG staining in
the high treatment groups (Fig. 2A). IL-1a treatment at 1 ng/ml also
resulted in a 68% decrease in the compressive modulus (Fig. 2B).
Conclusions: iPSC-derived cartilage displayed a dramatic and dose-
dependent catabolic response to IL-1a, similar to that of native cartilage.
The observed matrix degradation, loss of mechanical properties, andFigure 1. Release of MMPs and GAGs from iPSC-derive cartilage in an in vitro model of
OA. (A) All three IL-1a doses resulted in a signiﬁcant increase in MMP release from iPSC
neocartilage. (B) IL-1 a doses above 100 pg/ml resulted in an increased loss of GAG
from the pellets and into the media. Groups not connected by the same letter as
statistically different with P < 0.05, Mean  SEM.production of inﬂammatory mediators were all consistent with an OA
phenotype. This system also showed the ability to be tailored, as dose
dependent responses of the pellets to IL-1amay be useful for modeling
different stages of the disease or different joint space environments.
This work provides an initial demonstration of the potential of iPSCs for
creating patient-speciﬁc in vitro models of arthritis, which may facili-
tate the discovery of tailored OA therapeutics.
Figure 2. IL-1a induced degeneration of iPSC neocartilage. (A) Safranin-0 staining
conﬁrmed GAG loss from iPSC pellets at high IL-1a doses (positive staining is red, scale
bar ¼ 100 mm). (B) The compressive stiffness of iPSC-derived cartilage signiﬁcantly
decreased following IL-1a treatments above 100 pg/ml. Groups not connected by the
same letter as statistically different with P < 0.05. Mean SEM.
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TUNABLE EXPRESSION OF IL-1RA IN GENETICALLY MODIFIED
MESENCHYMAL STEM CELLS FOR CARTILAGE TISSUE ENGINEERING
K.A. Glass, J.M. Brunger, C.A. Gersbach, F. Guilak. Duke Univ., Durham,
NC, USA
Purpose: Inﬂammatory mediators such as interleukin-1 (IL-1) promote
catabolic signaling in articular chondrocytes during the pathogenesis of
osteoarthritis (OA) and, additionally, prevent mesenchymal stem cell
(MSC) chondrogenesis. Thus, IL-1 signaling in the OA joint may inhibit
the development or promote the degradation of engineered cartilage as
well as native tissue. The goal of this study was to genetically modify
human MSCs to induce constitutive or doxycycline-inducible expres-
sion of the natural anti-inﬂammatory modulator IL-1 receptor antago-
nist (IL-1Ra) as a cell source for functional cartilage tissue engineering
within an inﬂammatory environment.
Methods: IL-1Ra and eGFP coding sequences were cloned into lentiviral
expression vectors. 293T cells were transfected to produce self-
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supplementing culture medium with LV and polybrene. Transduction
efﬁciency was measured as % eGFP+ MSCs via ﬂow cytometry. IL-1Ra
secretion into culture media was quantiﬁed by ELISA. The chondrogenic
potential of MSCs following transduction with constitutive IL-1Ra or
eGFP LV was assessed in pellet culture. After 21 days in chondrogenic
medium (+10 ng/mL rhTGF-b3) or a basal medium, pellets were pro-
cessed for histology and stained to evaluate sulfated glycosaminoglycan
(s-GAG) and collagen production as measures of chondrogenesis.
Results: Transduced MSCs constitutively produced IL-1Ra in monolayer
culture for 27 days at concentrations of 3-10 ng per 10K cells every 3
days (Fig 1, A). Doxycycline-induced IL-1Ra production exceeded
constitutive expression for the ﬁrst 21 days. Non-transduced cells did
not produce detectable levels of IL-1Ra. The magnitude of inducible IL-
1Ra secretionwas effectively tuned from 2-200 ng/mL with doxycycline
doses ranging from 1-1000 ng/mL (Fig 1, B). IL-1Ra-transduced, eGFP-
transduced (90% eGFP+), or control MSCs were differentiated in pellet
culture for 21 days. Pellets in chondrogenic culture conditions produced
s-GAGs far exceeding the production in basal medium, with similar
levels observed in transduced and control cell populations (Fig 2, A). IL-
1Ra secretion in transduced pellets ranged from approximately 100-250
ng/mL throughout the culture period (a magnitude shown to inhibit
pathophysiologic IL-1 levels) (Fig 2, B). These ﬁndings show that IL-1Ra-
producing MSCs can undergo chondrogenesis following transduction
while simultaneously producing therapeutic levels of IL-1Ra.
Conclusions: We have developed MSCs capable of tunable IL-1Ra
production at therapeutically relevant concentrations. We have shown
that these MSCs retain their chondrogenic potential in pellet culture.
Future studies will examine the dynamic response of MSCs in response
to IL-1 challenge during chondrogenesis in pellet culture and in a tissue-
engineered construct. This system shows potential to enable growth
and differentiation of tissue-engineered cartilage constructs within the
inﬂammatory environment of an OA joint. In addition to a protective
effect on the engineered cartilage, release of IL-1Ra into the
surrounding tissue may have therapeutic effects throughout the joint.Figure 1. A. IL-1Ra secretion into media over 72 hours, from 3 to 27 days in culture
(mean  SEM, n¼3). B. IL-1Ra secretion tuned by doxycycline dose. Shown is
concentration released into media during 72 hours of induction (mean  SEM, n¼3).Figure 2. A. Safranin-O/fast green/haematoxylin staining for s-GAGs, collagen, and cell
nuclei in MSC pellets following 21 days in culture in chondrogenic (top row) or basal
medium (bottom row). 6 mm sections, scale bar ¼ 500 mm. B. IL-1Ra secretion into
media at 3 day intervals (mean  SEM, n¼3).
551
CHANGES IN CHONDROGENESIS DIFFERENTIATION POTENTIAL OF
BONE MARROW MESENCHYMAL STEM CELLS ACCORDING TO
DONOR AGE
Y. Li y, N. Charif y, D. Mainard y,z, N. de Isla y, J.-F. Stoltz y,z. yCNRS UMR
7561, Vandoeuvre, France; zCHU Nancy, Vandoeuvre, France
Purpose: Mesenchymal stem cells (MSC) are good candidates to be
used in regenerative medicine due to their differentiation potential.
Different studies propose these cells for the development of osteo-
articular tissues. However, while MSC from bone marrow are well
characterized, recent studies have evocated a decrease in proliferation
and differentiation capability of these cells when donor's age increase.
The aim of this work was to study the inﬂuence of donor's age on the
chondrogenic differentiation of bone marrow mesenchymal stem cells.
Methods: Two groups of donors were analyzed (<20 years and >60
years). Proliferation and clonogenicity of cells were tested for a culture
period of 10 weeks. Chondrogenic differentiation of cells was induced in
pellet culture using a chondrogenic differentiationmedium and TGF-b3.
After that, proteoglycan production was assayed using alcian blue
staining and gene expression of chondrocyte markers quantiﬁed by
qRT-PCR.
Results: Cells from the young donor's group an increased proliferation
capacity and clonogenicity as compared with cells from old donors. In
parallel, young donor group's cells were characterized by high level
expression of type II collagen, aggrecan and SOX-9 genes while cells
from the old donors group showed a poor chondrogenic differentiation.
Conclusions: This study shows that differences on proliferation and
chondrogenic differentiation exist between mesenchymal stem cells
isolated from bone marrow obtained from young or old donors. This
could be considered in the choise of MSC for cartilage tissue engi-
neering.
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